Ningxia Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ningxia Wu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Feng Cao
Department of Medicine School, Nankai University, Tianjin 300071, China
1 shared publication - Fengbo Miao
School of Electronics and Information Engineering, Tiangong University, Tianjin 300387, China
1 shared publication - Huijia Yin
Institute of Geriatric Medicine, National Clinical Research Centre for Geriatric Diseases, National Key Lab for Chronic Kidney Disease, The Second Medical Centre, Chinese PLA General Hospital, Beijing 100853, China
1 shared publication - Huiquan Wang
School of Life Sciences, Tiangong University, Tianjin, China
1 shared publication - Shengshu Wang
Institute of Geriatric Medicine, National Clinical Research Centre for Geriatric Diseases, National Key Lab for Chronic Kidney Disease, The Second Medical Centre, Chinese PLA General Hospital, Beijing 100853, China
1 shared publication - Shuang Song
School of Computer and Communication Engineering, University of Science and Technology Beijing, Beijing 100083, China
1 shared publication
Latest Publications
- Open Access
- 16 November 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (11) , 1363
A CMR-Based Multimodal Prediction for Optimized Non-Invasive Strategy in Patients with Suspected Obstructive Coronary Artery Disease
(1) Background: Cardiac magnetic resonance (CMR) is a non-invasive modality for myocardial tissue characterization in coronary artery disease (CAD), but optimizing its efficiency for clinical decision-making in high-risk patients with suspected obstructive coronary artery disease still remains challenging. (2) Objectives: This study aimed to develop and internally validate an interpretable multimodal prediction integrating CMR imaging, clinical variables, and laboratory biomarkers for risk stratification in high-risk patients with persistent suspicion of obstructive CAD after CMR. (3) Methods: Among 1296 patients with suspected CAD who underwent CMR, 325 were confirmed to have CAD. Of these, 239 underwent invasive CAG (derivation cohort) and 86 underwent coronary computed tomography angiography (CTA, Cross-Modality Applicability-Boundary Testing cohort, deliberately designed to define the model’s applicable scope rather than conventional multicenter external validation). Three hierarchical models were developed: laboratory-only (Model 1), imaging-only (Model 2), and multimodal integration (Model 3). Performance was evaluated using area under the curve (AUC), calibration curves, decision curve analysis, and SHapley Additive exPlanations (SHAP). A point-score SHAP-visualization plot was generated to illustrate relative feature contributions of the multimodal model. (4) Results: The optimal multimodal achieved an AUC of 0.920 (95% CI 0.873–0.960), significantly outperforming laboratory-only (AUC 0.719, p < 0.001) and imaging-only models (AUC 0.888, p < 0.001). Cross-modality applicability-boundary testing in the CTA cohort (n = 86) demonstrated expected performance attenuation (AUC = 0.611), indicating that this model is intended for high-risk patients referred for invasive angiography rather than unselected CTA screening. SHAP analysis identified cardiomyopathy type, E-wave velocity, and aortic annulus diameter as top predictors. (5) Conclusions: This interpretable multimodal prediction reliably showed promising internal discrimination for obstructive CAD risk stratification but demonstrated imperfect calibration and limited cross-modality performance. Prospective multicenter external validation is mandatory before any clinical-decision-support deployment.
- 16 November 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (11) , 1363
Open AccessA CMR-Based Multimodal Prediction for Optimized Non-Invasive Strategy in Patients with Suspected Obstructive Coronary Artery Disease
(1) Background: Cardiac magnetic resonance (CMR) is a non-invasive modality for myocardial tissue characterization in coronary artery disease (CAD), but optimizing its efficiency for clinical decision-making in high-risk patients with suspected obstructive coronary artery disease still remains challenging. (2) Objectives: This study aimed to develop and internally validate an interpretable multimodal prediction integrating CMR imaging, clinical variables, and laboratory biomarkers for risk stratification in high-risk patients with persistent suspicion of obstructive CAD after CMR. (3) Methods: Among 1296 patients with suspected CAD who underwent CMR, 325 were confirmed to have CAD. Of these, 239 underwent invasive CAG (derivation cohort) and 86 underwent coronary computed tomography angiography (CTA, Cross-Modality Applicability-Boundary Testing cohort, deliberately designed to define the model’s applicable scope rather than conventional multicenter external validation). Three hierarchical models were developed: laboratory-only (Model 1), imaging-only (Model 2), and multimodal integration (Model 3). Performance was evaluated using area under the curve (AUC), calibration curves, decision curve analysis, and SHapley Additive exPlanations (SHAP). A point-score SHAP-visualization plot was generated to illustrate relative feature contributions of the multimodal model. (4) Results: The optimal multimodal achieved an AUC of 0.920 (95% CI 0.873–0.960), significantly outperforming laboratory-only (AUC 0.719, p < 0.001) and imaging-only models (AUC 0.888, p < 0.001). Cross-modality applicability-boundary testing in the CTA cohort (n = 86) demonstrated expected performance attenuation (AUC = 0.611), indicating that this model is intended for high-risk patients referred for invasive angiography rather than unselected CTA screening. SHAP analysis identified cardiomyopathy type, E-wave velocity, and aortic annulus diameter as top predictors. (5) Conclusions: This interpretable multimodal prediction reliably showed promising internal discrimination for obstructive CAD risk stratification but demonstrated imperfect calibration and limited cross-modality performance. Prospective multicenter external validation is mandatory before any clinical-decision-support deployment.